Change in respiratory syncytial virus disease burden toward the second year of life after nirsevimab immunization: insights from a two-year follow-up in a self-controlled case series study

Introduction Nirsevimab, a long-acting monoclonal antibody against respiratory syncytial virus (RSV), is effective in preventing hospitalizations during infants' first RSV season, but concerns about long-term effects persist. Long-term studies show no significant differences in second-season events between immunized and non-immunized infants. Methods A self-controlled case series study tracked hospital admissions for newborns born between April 1, 2023, and March 31, 2024, from October 1, 2023, to September 30, 2025. It compared events between RSV seasons for infants immunized with nirsevimab in their first RSV season. Results A total of 1,152 RSV-associated hospitalizations were analyzed, involving 1,128 participants. Cases among immunized participants -crude data- rose by 3.42 times (95% CI: 2.84 to 4.14) during the second RSV season (503 vs 147). In the adjusted and self-controlled model, the hospitalization rate during the second season is 7.99 times higher than during nirsevimab's effectiveness period (95% CI: 5.80 to 11.02). Similarly, PICU admissions increased by 2.14-fold (95% CI: 0.87 to 5.30), although low statistical power limits conclusiveness. No lingering effect from the immunization was observed during the second season. The risk of hospitalizations, considering their age, during peak periods in the second season was 4.31 to 12.53 times higher than during the nirsevimab protection period. No significant differences were noted for PICU admissions. Discussion No evidence of nirsevimab residual efficacy was observed during the second RSV season. The age-related reduction in hospitalization risk among the immunized did not prevent the increase in disease burden in the second year of life. This contradicts earlier evidence and therefore necessitates a reevaluation of policies and preventive measures.

Authors

Institutions

Publication Details

Journal
Frontiers in Public Health
Published
2026-11-18
DOI
https://doi.org/10.3389/fpubh.2026.1920752
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Change in respiratory syncytial virus disease burden toward the second year of life after nirsevimab immunization: insights from a two-year follow-up in a self-controlled case series study

José Francisco Barbas del Buey, Jesús Íñigo Martínez, Mariel Morey Montalvo, Araceli Arce Arnáez et al.
9 links
Frontiers in Public Health
Respiratory viral infections research
article

Change in respiratory syncytial virus disease burden toward the second year of life after nirsevimab immunization: insights from a two-year follow-up in a self-controlled case series study

José Francisco Barbas del Buey, Jesús Íñigo Martínez, Mariel Morey Montalvo, Araceli Arce Arnáez, Susana Jiménez Bueno, Marta Elena Huerta Cofiño, Marcos Alonso García
article en

Abstract

Introduction Nirsevimab, a long-acting monoclonal antibody against respiratory syncytial virus (RSV), is effective in preventing hospitalizations during infants' first RSV season, but concerns about long-term effects persist. Long-term studies show no significant differences in second-season events between immunized and non-immunized infants. Methods A self-controlled case series study tracked hospital admissions for newborns born between April 1, 2023, and March 31, 2024, from October 1, 2023, to September 30, 2025. It compared events between RSV seasons for infants immunized with nirsevimab in their first RSV season. Results A total of 1,152 RSV-associated hospitalizations were analyzed, involving 1,128 participants. Cases among immunized participants -crude data- rose by 3.42 times (95% CI: 2.84 to 4.14) during the second RSV season (503 vs 147). In the adjusted and self-controlled model, the hospitalization rate during the second season is 7.99 times higher than during nirsevimab's effectiveness period (95% CI: 5.80 to 11.02). Similarly, PICU admissions increased by 2.14-fold (95% CI: 0.87 to 5.30), although low statistical power limits conclusiveness. No lingering effect from the immunization was observed during the second season. The risk of hospitalizations, considering their age, during peak periods in the second season was 4.31 to 12.53 times higher than during the nirsevimab protection period. No significant differences were noted for PICU admissions. Discussion No evidence of nirsevimab residual efficacy was observed during the second RSV season. The age-related reduction in hospitalization risk among the immunized did not prevent the increase in disease burden in the second year of life. This contradicts earlier evidence and therefore necessitates a reevaluation of policies and preventive measures.

Frontiers in Public HealthVol. 14
Comunidad de Madrid (ES), Fundación para la Investigación e Innovación Biosanitaria de Atención Primaria (ES)
Good health and well-being
Respiratory viral infections research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon